JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F23%3A00078401" target="_blank" >RIV/65269705:_____/23:00078401 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14110/23:00130986
Výsledek na webu
<a href="https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/ch221678" target="_blank" >https://content.iospress.com/articles/clinical-hemorheology-and-microcirculation/ch221678</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3233/CH-221678" target="_blank" >10.3233/CH-221678</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia
Popis výsledku v původním jazyce
The clinical course of essential thrombocythemia (ET) is complicated with thrombosis which significantly impacts patients' mortality. Studies have identified JAK2(V617F) mutation as an independent risk factor for thrombosis. Circulating extracellular vesicles (EVs) were evaluated in several studies regarding myeloproliferative neoplasms and thrombosis as potential biomarkers. The present study investigates the relationship between JAK2(V617F) mutation and EVs levels in 119 ET patients. Our analyses revealed that JAK2(V617F-)positive patients are at a significantly increased risk of thrombosis within five years before the ET diagnosis (hazard ratio [95% CI]: 11.9 [1.7-83.7], P = 0.013), and that JAK2(V617F) mutation is an independent risk factor for thrombosis at ET diagnosis or during the follow-up (hazard ratio [95% CI]: 3.56 [1.47-8.62], P = 0.005). ET patients have higher levels of platelet-EVs, erythrocyte-EVs and procoagulant activity of EVs than the healthy population. Absolute and relative counts of platelet-EVs are increased in the presence of JAK2(V617F) mutation (P = 0.018, P = 0.024, respectively). In conclusion, our results support the role of JAK2(V617F) mutation in the pathogenesis of thrombosis in essential thrombocythemia through enhancing platelet activation.
Název v anglickém jazyce
JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia
Popis výsledku anglicky
The clinical course of essential thrombocythemia (ET) is complicated with thrombosis which significantly impacts patients' mortality. Studies have identified JAK2(V617F) mutation as an independent risk factor for thrombosis. Circulating extracellular vesicles (EVs) were evaluated in several studies regarding myeloproliferative neoplasms and thrombosis as potential biomarkers. The present study investigates the relationship between JAK2(V617F) mutation and EVs levels in 119 ET patients. Our analyses revealed that JAK2(V617F-)positive patients are at a significantly increased risk of thrombosis within five years before the ET diagnosis (hazard ratio [95% CI]: 11.9 [1.7-83.7], P = 0.013), and that JAK2(V617F) mutation is an independent risk factor for thrombosis at ET diagnosis or during the follow-up (hazard ratio [95% CI]: 3.56 [1.47-8.62], P = 0.005). ET patients have higher levels of platelet-EVs, erythrocyte-EVs and procoagulant activity of EVs than the healthy population. Absolute and relative counts of platelet-EVs are increased in the presence of JAK2(V617F) mutation (P = 0.018, P = 0.024, respectively). In conclusion, our results support the role of JAK2(V617F) mutation in the pathogenesis of thrombosis in essential thrombocythemia through enhancing platelet activation.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30205 - Hematology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2023
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Clinical Hemorheology and Microcirculation
ISSN
1386-0291
e-ISSN
1875-8622
Svazek periodika
84
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
NL - Nizozemsko
Počet stran výsledku
10
Strana od-do
359-368
Kód UT WoS článku
001076811500002
EID výsledku v databázi Scopus
2-s2.0-85172425703